Bio-Rad Laboratories (STU:BUWA) Cyclically Adjusted Revenue per Share: €91.30 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BUWA Bio-Rad Laboratories Inc STU:BUWA
71 GF Score
Price €330.80
GF Value €276.66
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Cyclically Adjusted Revenue per Share?

Bio-Rad Laboratories STU:BUWA +1.04% 71 Cyclically Adjusted Revenue per Share is €91.30 as of Jun. 2026. GuruFocus rates STU:BUWA with a GF Score™ of 71/100 and a GF Value™ of €276.66 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bio-Rad Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was €20.881. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €91.30 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bio-Rad Laboratories's average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bio-Rad Laboratories was 11.60% per year. The lowest was 2.10% per year. And the median was 7.20% per year.

As of today (2026-09-17), Bio-Rad Laboratories's current stock price is €330.80. Bio-Rad Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €91.30. Bio-Rad Laboratories's Cyclically Adjusted PS Ratio of today is 3.62.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Rad Laboratories was 9.77. The lowest was 2.18. And the median was 3.77.


Bio-Rad Laboratories  (STU:BUWA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bio-Rad Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=330.80/91.302
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Rad Laboratories was 9.77. The lowest was 2.18. And the median was 3.77.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Related Terms


Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.61 78.98 82.77 86.01 88.22

Bio-Rad Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.47 89.20 88.78 90.33 91.30

STU:BUWA vs PODD, GKOS, GMED: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Cyclically Adjusted PS Ratio falls into.


STU:BUWA
71GF Score
Bio-Rad Laboratories Inc STU:BUWA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Rad Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=20.881/333.9520*333.9520
=20.881

Current CPI (Jun. 2026) = 333.9520.

Bio-Rad Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 15.364 241.428 21.252
201612 17.933 241.432 24.805
201703 15.686 243.801 21.486
201706 15.284 244.955 20.837
201709 15.144 246.819 20.490
201712 17.526 246.524 23.741
201803 14.874 249.554 19.904
201806 15.996 251.989 21.199
201809 15.472 252.439 20.468
201812 18.114 251.233 24.078
201903 16.207 254.202 21.292
201906 16.900 256.143 22.034
201909 16.903 256.759 21.985
201912 18.662 256.974 24.252
202003 17.184 258.115 22.233
202006 16.220 257.797 21.011
202009 18.392 260.280 23.598
202012 21.959 260.474 28.153
202103 19.990 264.877 25.203
202106 19.713 271.696 24.230
202109 20.967 274.310 25.526
202112 21.425 278.802 25.663
202203 20.848 287.504 24.216
202206 21.766 296.311 24.531
202209 22.732 296.808 25.577
202212 24.046 296.797 27.056
202303 21.206 301.836 23.462
202306 21.319 305.109 23.334
202309 19.883 307.789 21.573
202312 21.987 306.746 23.937
202403 19.721 312.332 21.086
202406 20.886 314.175 22.201
202409 21.134 315.301 22.384
202412 22.351 315.605 23.650
202503 19.897 319.799 20.778
202506 21.114 322.561 21.860
202509 20.755 324.800 21.340
202512 22.048 324.054 22.721
202603 18.774 330.213 18.987
202606 20.881 333.952 20.881

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €91.30 mean?
Bio-Rad Laboratories (STU:BUWA) has a Cyclically Adjusted Revenue per Share of €91.30 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Cyclically Adjusted Revenue per Share too high?
Bio-Rad Laboratories' current Cyclically Adjusted Revenue per Share is €91.30. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Cyclically Adjusted Revenue per Share compare to PODD and GKOS?
Bio-Rad Laboratories' Cyclically Adjusted Revenue per Share of €91.30 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Cyclically Adjusted Revenue per Share is €91.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (STU:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €276.66, compared to a current price of €330.80 — trading 19.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €91.30. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bio-Rad Laboratories (STU:BUWA), the current Cyclically Adjusted Revenue per Share is €91.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (STU:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of €330.80 is trading 19.6% above its estimated GF Value™ of €276.66. GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.

Key valuation signals for STU:BUWA:

  • Cyclically Adjusted Revenue per Share: €91.30
  • GF Value™: €276.66 vs. price of €330.80 (19.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the STU:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Other Exchanges BIO.B:USABIO:USA
Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for STU:BUWA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€330.80
Price
€276.66
GF Value